Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06892951 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia

Study acronym: CaspoNEB
StatusNot Yet Recruiting
PhasePhase 1/2
Started2025-06
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 25, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
To assess the efficacy of administrating daily caspofungin aerosols versus placebo for seven days, in adjunction of conventional systemic antifungal therapy during curative treatment of Pneumocystis pneumonia, on the clinical outcome at the end of the nebulized therapy, in order to support a "GO / NO GO" decision towards a phase III trial of nebulized caspofungin in those patients.
Trial Details
NCT Number NCT06892951
Lead Sponsor University Hospital, Tours
Collaborators: University Hospital, Angers, Centre Hospitalier Universitaire de Besancon, University Hospital, Bordeaux, University Hospital, Brest, Centre Hospitalier Universitaire Dijon, University Hospital, Grenoble, University Hospital, Lille, University Hospital, Limoges, Hospices Civils de Lyon, University Hospital, Montpellier, Nantes University Hospital, Centre Hospitalier Universitaire de Nice, Hospital Avicenne, Henri Mondor University Hospital, Hopital Foch, Hôpital Necker-Enfants Malades, Pitié-Salpêtrière Hospital, Poitiers University Hospital, Reims University hospital, Ohre Pharma, Aerogen, Wako Diagnostics, Cape Cod Incorporated, Institut National de la Santé Et de la Recherche Médicale, France, Tours university, Amiens University Hospital, Rennes University Hospital
Conditions Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection, Pneumocystis Infections
Enrollment 100 participants
Start Date 2025-06
Primary Completion 2026-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-25